Details of the Drug Reposition

General Information of This Drug (ID: DMOHT5V)

• Drug Name: DKN-01 (DMOHT5V)
• Drug Type: Antibody

Information on Drug Reposition of This Drug

4 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Esophageal cancer	DISGB2VN	2B70	Phase 2	[1]
Biliary tract cancer	DISBNYQL	2C17	Phase 2	[1]
Ovarian cancer	DISZJHAP	2C73	Phase 2	[2]
Endometrial cancer	DISW0LMR	2C76	Phase 2	[2]

4 Phase 1/2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Multiple myeloma	DISEWP9B	2A83	Phase 1/2	[3]
Oesophagogastric junction cancer	DISSLH1X	2B71.Z	Phase 1/2	[2]
Cholangiocarcinoma	DIS71F6X	2C12.10	Phase 1/2	[4]
Prostate cancer	DISF190Y	2C82.0	Phase 1/2	[5]

References

• [1] ClinicalTrials.gov (NCT03818997) Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer (DYNAMIC). U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] ClinicalTrials.gov (NCT01711671) A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT03837353) A Parallel Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1. U.S. National Institutes of Health.